LXRX
Lexicon Pharmaceuticals, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Lexicon Pharmaceuticals, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Linked news
No other changes.
No other changes.
| Manager | Value | % base | |
|---|---|---|---|
| Artal | $420.4M | 47.82% | +13.20% |
| FMR | $124.3M | 14.14% | +14.93% |
| Siren | $106.3M | 12.10% | 0.00% |
| Sessa Capital IM | $45.5M | 5.18% | +5.85% |
| BlackRockindex-like | $41.6M | 4.74% | +422.20% |
| Manager | Value | % base | |
|---|---|---|---|
| Artal | $420.4M | 47.82% | +13.20% |
| FMR | $124.3M | 14.14% | +14.93% |
| Siren | $106.3M | 12.10% | 0.00% |
| Sessa Capital IM | $45.5M | 5.18% | +5.85% |
| BlackRockindex-like | $41.6M | 4.74% | +422.20% |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Lexicon Pharmaceuticals, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Lexicon Pharmaceuticals, Inc..
Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Bull2
Bear1
Lexicon Pharmaceuticals, Inc.
1.46
+0.02 · +1.39%
post 1.46 0.00%
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Expected move
Inputsspot 1.46exp Nov 20ATM strike 1.5ATM straddle 0.43IV 167%